Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Biomarker; Therapeutic Use
- 12 Sep 2017 Results of exploratory analysis assessing correlation between (secreted protein acidic and rich in cysteine) SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine, were presented at the 42nd European Society for Medical Oncology Congress.
- 21 Jan 2017 Status changed from recruiting to active, no longe recruiting, according to results presented at the 2017 Gastrointestinal Cancers Symposium.
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.